Source-grounded facts extracted from RIGEL PHARMACEUTICALS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Lisa Rojkjaer departed as Executive Vice President and Chief Medical Officer at RIGEL PHARMACEUTICALS INC.
“Effective June 25, 2026, Lisa Rojkjaer, M.D. ceased serving as Executive Vice President and Chief Medical Officer of the Company and separated from the Company.”
Alison L. Hannah resigned as Director at RIGEL PHARMACEUTICALS INC.
“In connection with her appointment, Dr. Hannah resigned from the Company’s Board of Directors (the “Board”), effective July 1, 2026.”
Alison L. Hannah was appointed as Executive Vice President and Chief Medical Officer at RIGEL PHARMACEUTICALS INC.
“On July 1, 2026, Rigel Pharmaceuticals, Inc. (the "Company") announced that Alison L. Hannah, M.D. was appointed Executive Vice President and Chief Medical Officer of the Company.”
RIGEL PHARMACEUTICALS INC completed an acquisition involving Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc. and Pfizer Inc. for $70.0 million.
“Following the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the satisfaction of the other closing conditions under the License Agreement, the License Agreement became effective and the transactions contemplated thereby were completed. In connection therewith, the Company paid the Licensors a one-time upfront payment of $70.0 million.”
RIGEL PHARMACEUTICALS INC shareholders approved Ratification of Selection of Ernst & Young at the 2026-12-31 meeting.
“Ratification of Selection of Ernst & Young The Company’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. For Against Abstain Broker Non-Votes 12,590,773 1,506,852 29,809 —”
RIGEL PHARMACEUTICALS INC shareholders approved Say-on-Pay.
“Say-on-Pay The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. For Against Abstain Broker Non-Votes 9,013,480 1,291,609 416,316 3,406,029”
RIGEL PHARMACEUTICALS INC shareholders approved Approval of the 2000 Employee Stock Purchase Plan.
“Approval of the 2000 Employee Stock Purchase Plan The Company’s stockholders approved the Amended 2000 Employee Stock Purchase Plan. For Against Abstain Broker Non-Votes 9,840,922 475,464 405,019 3,406,029”
RIGEL PHARMACEUTICALS INC shareholders approved Approval of the Amended 2018 Equity Incentive Plan.
“Approval of the Amended 2018 Equity Incentive Plan The Company’s stockholders approved the Amended 2018 Equity Incentive Plan. For Against Abstain Broker Non-Votes 6,497,964 3,813,701 409,740 3,406,029”
RIGEL PHARMACEUTICALS INC shareholders approved Election of Directors.
“Election of Directors Each of the nominees for director, to serve until the Company’s 2029 Annual Meeting of Stockholders or until his or her respective successor has been elected and qualified, was elected as follows: Name of Director For Withheld Abstain Broker Non-Votes Alison Hannah, M.D. 9,202,113 1,469,709 49,583 3,406,029 Walter Moos, Ph.D. 10,436,673 242,736 41,996 3,406,029 Raul Rodriguez 10,486,503 192,614 42,288 3,406,029”
RIGEL PHARMACEUTICALS INC entered into Agreement with Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc. and Pfizer Inc. valued at $70 million upfront payment, $15 million transition completion payment, up to $320 million in milest (effective 2026-05-11).
“On May 11, 2026, Rigel Pharmaceuticals, Inc. ("Rigel" or the "Company") entered into a License Agreement (the "Agreement") with Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc. and Pfizer Inc. (collectively, the "Licensors").”
RIGEL PHARMACEUTICALS INC reported first quarter ended March 31, 2026 results: revenue $58.8 million, net income $8.7 million of net income.
“of any general incorporation language in such filing. --- EX-99.1 (EX-99.1) --- Rigel Reports First Quarter 2026 Financial Results • First quarter 2026 total revenues of $58.8 million , including net product sales of $54.9 million and contract revenues from collaborations of $3.9 million • Generated $8.7 million of net income in the first quarter of 2026 • On”
RIGEL PHARMACEUTICALS INC terminated License and Collaboration Agreement with Eli Lilly and Company valued at Lilly's election to terminate the License and Collaboration Agreement in its entirety; Rigel expects (effective 2026-06-15).
“On April 16, 2026, Rigel Pharmaceuticals, Inc. (“Rigel”) received written notice from Eli Lilly and Company (“Lilly”) of Lilly’s election to terminate that certain License and Collaboration Agreement, dated February 18, 2021 (the “Agreement”), between Rigel and Lilly.”
Mark J. Frohlich was appointed as Director at RIGEL PHARMACEUTICALS INC.
“On March 6, 2025 (the “Effective Date”), Mark J. Frohlich was appointed to serve on the board of directors (the “Board”) of Rigel Pharmaceuticals, Inc.”
Brian Kotzin resigned as Director at RIGEL PHARMACEUTICALS INC.
“On September 16, 2024, Dr. Brian Kotzin notified Rigel Pharmaceuticals, Inc. (“ Rigel ”) of his decision to resign as a member of the Board of Directors of Rigel (the “ Board ”) and from the committees on which he serves, effective September 16, 2024.”
RIGEL PHARMACEUTICALS INC reported first quarter ended March 31, 2024 results: revenue $29.5 million.
“2 tm2413689d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rigel Reports First Quarter 2024 Financial Results and Provides Business Update · First quarter 2024 total revenue of $29.5 million, which includes TAVALISSE ® net product sales of $21.1 million and REZLIDHIA ® net product sales of $4.9 million · Expanded Rigel's portfolio with acquisition of GAVRETO ® , a”
RIGEL PHARMACEUTICALS INC amended Amendment No. 4 to Credit and Security Agreement with MidCap Financial Trust valued at Extended maturity to September 1, 2027; interest-only period to October 1, 2025; interest rate SOFR+ (effective 2024-04-11).
“On April 11, 2024, Rigel Pharmaceuticals, Inc. (“ Rigel ”) entered into Amendment No. 4 (the “ Amendment ”) to that certain Credit and Security Agreement, dated as of September 27, 2019 (as further amended, supplemented or otherwise modified from time to time prior to the Amendment, the “ Existing Credit Agreement ,” and as amended by the Amendment, the “ Amended Credit Agreement ”) with Midcap Financial Trust (“ MidCap ”), as administrative agent, and the lenders party thereto (“ Lenders ”), pursuant to which MidCap and the Lenders agreed to amend the Existing Credit Agreement to, among other things, (i) extend the maturity date for the term loans to September 1, 2027 (the “ Maturity Date ”), (ii) extend the interest only period for the term loans to October 1, 2025, (iii) reset the prepayment fee applicable to the term loans, (iv) increase the exit fee payable on the term loans, (v) revise the interest rate payable on the term loans, and (vi) update certain financial covenants in con”
RIGEL PHARMACEUTICALS INC reported financial results for fourth quarter and full year ended December 31, 2023.
“On March 5, 2024, Rigel Pharmaceuticals, Inc. (“ Rigel ”) announced certain financial results for its fourth quarter and year ended December 31, 2023.”
RIGEL PHARMACEUTICALS INC reported fourth quarter and fiscal year ended December 31, 2023 results: revenue $35.7 million.
“--- EX-99.1 2 tm242328d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rigel Pharmaceuticals Provides Business Update · Preliminary fourth quarter 2023 total revenue of approximately $35.7 million which includes record TAVALISSE ® net product sales of $25.7 million and REZLIDHIA ® net product sales of $3.9 million · Strategic alliance with MD Anderson to advance”
RIGEL PHARMACEUTICALS INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“November 27, 2023, Rigel Pharmaceuticals, Inc. (“Rigel”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying Rigel that, for the last 30 consecutive business days, the bid price for Rigel’s common stock, par value $0.001 per share (the “Common Stock”), closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the “Compli”
RIGEL PHARMACEUTICALS INC reported nine months ended September 30, 2023 results: revenue $81.1 million, net income net loss of $25.8 million, EPS $0.15 per basic and diluted share.
“compared to a net loss of $60.0 million, or $0.35 per basic and diluted share, for the same period of 2022. For the nine months ended September 30, 2023, total revenues were $81.1 million, consisting of $68.1 million in TAVALISSE net product sales, $6.7 million in REZLIDHIA net product sales, $5.3 million in contract revenues from collaborations, and $1.0 million”
RIGEL PHARMACEUTICALS INC reported third quarter ended September 30, 2023 results: revenue $28.1 million, net income net loss of $5.7 million, EPS $0.03 per basic and diluted share.
“2 tm2329984d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update · Third quarter 2023 Total Revenue of $28.1 million which includes record TAVALISSE ® net product sales of $24.5 million and REZLIDHIA ® net product sales of $2.7 million · New data on olutasidenib in mIDH1 relapsed or”
RIGEL PHARMACEUTICALS INC reported the six months ended June 30, 2023 results: revenue $52.9 million, net income net loss of $20.1 million, EPS $0.12 per basic and diluted share.
“For the six months ended June 30, 2023, Rigel reported a net loss of $20.1 million, or $0.12 per basic and diluted share, compared to a net loss of $40.9 million, or $0.24 per basic and diluted share, for the same period of 2022. For the six months ended June 30, 2023, total revenues were $52.9 million”
RIGEL PHARMACEUTICALS INC reported the second quarter ended June 30, 2023 results: revenue $26.9 million, net income net loss of $6.6 million, EPS $0.04 per basic and diluted share.
“For the second quarter of 2023, Rigel reported a net loss of $6.6 million, or $0.04 per basic and diluted share, compared to a net loss of $13.5 million, or $0.08 per basic and diluted share, for the same period of 2022. For the second quarter of 2023, total revenues were $26.9 million”
RIGEL PHARMACEUTICALS INC shareholders approved Ratification of Selection of Ernst & Young at the 2023-12-31 meeting.
“Ratification of Selection of Ernst & Young The Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023. For Against Abstain Broker Non-Votes 119,779,873 2,561,946 10,037,420 —”
RIGEL PHARMACEUTICALS INC shareholders approved Say-on-Frequency.
“Say-on-Frequency The Company's stockholders approved, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers as disclosed in the Proxy Statement. 1 Year 2 Years 3 Years Abstain Broker Non-Votes 82,264,431 168,884 1,905,936 11,738,369 36,301,619”
RIGEL PHARMACEUTICALS INC shareholders approved Say-on-Pay.
“Say-on-Pay The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement. For Against Abstain Broker Non-Votes 76,640,368 7,558,152 11,879,100 36,301,619”
RIGEL PHARMACEUTICALS INC shareholders approved Approval of the Amended 2018 Plan.
“Approval of the Amended 2018 Plan The Company's stockholders approved the Amended 2018 Plan. For Against Abstain Broker Non-Votes 56,561,234 30,007,992 9,508,394 36,301,619”
RIGEL PHARMACEUTICALS INC shareholders approved Election of Directors.
“Election of Directors Each of the three nominees for director, to serve until the Company's 2026 Annual Meeting of Stockholders or until his or her respective successor has been elected and qualified, was elected as follows: Name of Director For Withheld Broker Non-Votes Alison L. Hannah 75,693,596 20,384,024 36,301,619 Walter H. Moos 79,771,626 16,305,994 36,301,619 Raul R. Rodriguez 80,052,247 16,025,373 36,301,619”
RIGEL PHARMACEUTICALS INC reported financial results for first quarter ended March 31, 2023.
“On May 2, 2023, Rigel Pharmaceuticals, Inc. (“Rigel”) announced certain financial results for its first quarter ended March 31, 2023. A copy of Rigel’s press release, titled “Rigel Reports First Quarter 2023 Financial Results and Provides Business Update,” is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto.”
RIGEL PHARMACEUTICALS INC reported fourth quarter and year ended December 31, 2022 results: revenue $51.3 million, net income $1.4 million, or $0.01 per basic and diluted share, EPS $0.01 per basic and diluted share.
“EXHIBIT 99.1 Exhibit 99.1 Rigel Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update ● Fourth quarter 2022 Total Revenue of $51.3 million which includes TAVALISSE ® net product sales of $21.9 million and REZLIDHIA TM net product sales of $0.9 million ● REZLIDHIA U.S. commercial launch continues to progress and”
Wolfgang Dummer resigned as Executive Vice President and Chief Medical Officer at RIGEL PHARMACEUTICALS INC.
“Wolfgang Dummer, M.D., Ph.D. informed Rigel Pharmaceuticals, Inc. (the “Company”) of his intention to resign from his position as the Company’s Executive Vice President and Chief Medical Officer.”
RIGEL PHARMACEUTICALS INC reported the fourth quarter ended December 31, 2022 results: revenue $51.3 million.
“Preliminary fourth quarter 2022 Total Revenue of approximately $51.3 million”
RIGEL PHARMACEUTICALS INC reported nine months ended September 30, 2022 results: revenue $69.0 million, net income net loss of $60.0 million, EPS ($0.35) per basic and diluted share.
“For the nine months ended September 30, 2022, Rigel reported a net loss of $60.0 million, or $0.35 per basic and diluted share, compared to a net income of $4.7 million, or $0.03 per basic and diluted share, for the same period of 2021. For the nine months ended September 30, 2022, total revenues were $69.0 million, consisting of $53.9 million in TAVALISSE net product sales, $12.5 million in contract revenues from collaborations and $2.5 million in government contract revenue.”
RIGEL PHARMACEUTICALS INC reported third quarter ended September 30, 2022 results: revenue $22.4 million, net income net loss of $19.0 million, EPS ($0.11) per basic and diluted share.
“For the third quarter of 2022, Rigel reported a net loss of $19.0 million, or $0.11 per basic and diluted share, compared to a net loss of $21.0 million, or $0.12 per basic and diluted share, for the same period of 2021. For the third quarter of 2022, total revenues were $22.4 million, consisting of $19.2 million in TAVALISSE net product sales, $0.7 million in contract revenues from collaborations and $2.5 million in government contract revenue.”
RIGEL PHARMACEUTICALS INC: Amended and restated bylaws effective October 31, 2022 with revisions to stockholder proposal disclosures, meeting conduct, and exclusive forum provisions (effective 2022-10-31).
“On October 31, 2022, the Board of Directors of the Company (the "Board") approved the second amendment and restatement of the Bylaws of the Company (the "Amended and Restated Bylaws"). The Amended and Restated Bylaws are effective as of October 31, 2022.”
RIGEL PHARMACEUTICALS INC entered into sublease agreement with Atara Biotherapeutics, Inc. valued at approximately $1.8 million (based on 13,670 rentable square feet, term through May 24, 2025) (effective 2022-10-28).
“On October 28, 2022, Rigel Pharmaceuticals, Inc. (“Rigel” or the “Company”) entered into a sublease agreement with Atara Biotherapeutics, Inc. to sublease approximately 13,670 rentable square feet of office space located in South San Francisco, California.”
Dolly A. Vance retired as general counsel at RIGEL PHARMACEUTICALS INC.
“On October 11, 2022, Dolly A. Vance provided notice of her retirement from her position as general counsel, executive vice president, corporate affairs, and corporate secretary of Rigel, effective the date of this current report.”
Kamil Ali-Jackson was appointed as Director at RIGEL PHARMACEUTICALS INC.
“On the Effective Date, the Board appointed, upon the recommendation of the Board’s Corporate Governance, Health Care Compliance Oversight and Nominating Committee, Kamil Ali-Jackson to fill in the vacancy on the Board and to serve as a member of the Board until her successor is elected and has qualified, or sooner in the event of her death, resignation or removal.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.